Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study von Ji, Linong, MD, Ma, Jianhua, MD, Li, Hongmei, MD, PhD, Mansfield, Traci A., PhD, T’joen, Caroline L., MSc, Iqbal, Nayyar, MD, MSCE, Ptaszynska, Agata, MD, List, James F., MA, MD, PhD

Volltext

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis von Howard, Jr, James F, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan L, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said R, Pasnoor, Mamatha, Guglietta, Antonio, Van Hoorick, Benjamin, Steeland, Sophie, T'joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Efficacy of Adjunctive Aripiprazole to Either Valproate or Lithium in Bipolar Mania Patients Partially Nonresponsive to Valproate Lithium Monotherapy: A Placebo-Controlled Study von Vieta, Eduard, T'joen, Caroline, McQuade, Robert D., Carson, William H., Marcus, Ronald N., Sanchez, Raymond, Owen, Randall, Nameche, Laurence

Volltext

Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment von Wilding, John P.H, Norwood, Paul, T'joen, Caroline, Bastien, Arnaud, List, James F, Fiedorek, Fred T

Volltext

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers von Wilding, John P.H., Norwood, Paul, T'joen, Caroline, Bastien, Arnaud, List, James F., Fiedorek, Fred T.

Volltext

Long-term safety, tolerability, and efficacy of efgartigimod in patients with generalized myasthenia gravis: Concluding analyses from the ADAPT+ study von Bril, Vera, Pasnoor, Mamatha, Karam, Chafic, Peric, Stojan, De Bleecker, Jan L., Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said, Vu, Tuan, Ulrichts, Peter, Van Hoorick, Benjamin, T'Joen, Caroline, Kaprielian, Roger, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato, Howard, James F.

Volltext

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study von Howard, James, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said, Pasnoor, Mamatha, Guglietta, Antonio, Ulrichts, Peter, T'joen, Caroline, Brauer, Edward, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial von Yang, Wenying, Han, Ping, Min, Kyung-Wan, Wang, Bei, Mansfield, Traci, T'Joen, Caroline, Iqbal, Nayyar, Johnsson, Eva, Ptaszynska, Agata

Volltext

Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial: 达格列净治疗接受二甲双胍治疗失败的亚洲2型糖尿病患者的疗效和安全性:一项随机对照研究... von Yang, Wenying, Han, Ping, Min, Kyung‐Wan, Wang, Bei, Mansfield, Traci, T'Joen, Caroline, Iqbal, Nayyar, Johnsson, Eva, Ptaszynska, Agata

Volltext

Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT+ Study (S5.006) von Pasnoor, Mamatha, Bril, Vera, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said, Vu, Tuan, Ulrichts, Peter, Van Hoorick, Benjamin, T’joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato, Howard, James

Volltext

Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study (S25.004) von Howard, James, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said, Pasnoor, Mamatha, Guglietta, Antonio, Ulrichts, Peter, T’joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato

Volltext

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+) : interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis von Howard, James F, Bril, Vera, Vu, Tuan, Karam, Chafic, Peric, Stojan, De Bleecker, Jan, Murai, Hiroyuki, Meisel, Andreas, Beydoun, Said R, Pasnoor, Mamatha, Guglietta, Antonio, Van Hoorick, Benjamin, Steeland, Sophie, T’joen, Caroline, Utsugisawa, Kimiaki, Verschuuren, Jan, Mantegazza, Renato, the ADAPT+ Study Group, [missing]

Volltext

Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial von Klazen, Caroline AH, Dr, Lohle, Paul NM, MD, de Vries, Jolanda, Prof, Jansen, Frits H, MD, Tielbeek, Alexander V, MD, Blonk, Marion C, MD, Venmans, Alexander, MD, van Rooij, Willem Jan J, Prof, Schoemaker, Marinus C, MD, Juttmann, Job R, MD, Lo, Tjoen H, MD, Verhaar, Harald JJ, MD, van der Graaf, Yolanda, Prof, van Everdingen, Kaspar J, MD, Muller, Alex F, MD, Elgersma, Otto EH, MD, Halkema, Dirk R, MD, Fransen, Hendrik, MD, Janssens, Xavier, MD, Buskens, Erik, Prof, Mali, Willem P Th M, Prof

Volltext